Literature DB >> 1330367

Calcium-channel antagonists: mechanisms of action, vascular selectivities, and clinical relevance.

D J Triggle1.   

Abstract

The calcium-channel antagonists represent three separate structural categories of drugs. They share a common action--the blockade of calcium-ion flow through one specific type of calcium channel. The chemical heterogeneity of these agents is reflected in their pharmacologic and therapeutic diversity. The calcium-channel antagonists enjoy significant use in cardiovascular medicine for the treatment of hypertension, angina, and some cardiac arrhythmias. However, the 1,4-dihydropyridines, the most potent antihypertensive calcium-channel blockers, lack antiarrhythmic properties. The selectivity of action of calcium-channel antagonists rests upon a number of factors, including pathways of calcium mobilization, types of channel activated, state-dependent interactions, and the pathological state of the tissue. An understanding of these factors is important to the rational application of these drugs and to the development of newer agents with different specificities.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1330367     DOI: 10.3949/ccjm.59.6.617

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  10 in total

1.  Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide.

Authors:  J Chemin; A Monteil; E Perez-Reyes; J Nargeot; P Lory
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

2.  Uptake pathways and subcellular fractionation of Cd in the polychaete Nereis diversicolor.

Authors:  Lianzhen Li; Xiaoli Liu; Liping You; Linbao Zhang; Jianmin Zhao; Huifeng Wu
Journal:  Ecotoxicology       Date:  2011-08-20       Impact factor: 2.823

3.  5,6-EET potently inhibits T-type calcium channels: implication in the regulation of the vascular tone.

Authors:  Magali Cazade; Isabelle Bidaud; Pernille B Hansen; Philippe Lory; Jean Chemin
Journal:  Pflugers Arch       Date:  2013-12-11       Impact factor: 3.657

4.  Nitric oxide, a possible mediator of 1,4-dihydropyridine-induced photorelaxation of vascular smooth muscle.

Authors:  F Lovren; S K O'Neill; D Bieger; N Igbal; E E Knaus; C R Triggle
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

5.  Pharmacological Evaluation of Prosopis cineraria (L.) Druce in Gastrointestinal, Respiratory, and Vascular Disorders.

Authors:  Khalid Hussain Janbaz; Sajjad Haider; Imran Imran; Muhammad Zia-Ul-Haq; Laura De Martino; Vincenzo De Feo
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-05       Impact factor: 2.629

6.  Comparative analysis of mouse skeletal muscle fibre type composition and contractile responses to calcium channel blocker.

Authors:  Satu Mänttäri; Matti Järvilehto
Journal:  BMC Physiol       Date:  2005-02-14

7.  Validation of ethnopharmacological uses of Murraya paniculata in disorders of diarrhea, asthma and hypertension.

Authors:  Fatima Saqib; Mobeen Ghulam Ahmed; Khalid Hussain Janbaz; Saikat Dewanjee; Hawa Z E Jaafar; Muhammad Zia-Ul-Haq
Journal:  BMC Complement Altern Med       Date:  2015-09-09       Impact factor: 3.659

8.  Calcium inhibitor inhibits high glucose‑induced hypertrophy of H9C2 cells.

Authors:  Xiaohong Xu; Luoyang Ruan; Xiaohua Tian; Fengjuan Pan; Cailan Yang; Guosheng Liu
Journal:  Mol Med Rep       Date:  2020-06-26       Impact factor: 2.952

Review 9.  The prince and the pauper. A tale of anticancer targeted agents.

Authors:  Alfonso Dueñas-González; Patricia García-López; Luis Alonso Herrera; Jose Luis Medina-Franco; Aurora González-Fierro; Myrna Candelaria
Journal:  Mol Cancer       Date:  2008-10-23       Impact factor: 27.401

10.  Regulation of aldosterone secretion by Cav1.3.

Authors:  Catherine B Xie; Lalarukh Haris Shaikh; Sumedha Garg; Gizem Tanriver; Ada E D Teo; Junhua Zhou; Carmela Maniero; Wanfeng Zhao; Soosung Kang; Richard B Silverman; Elena A B Azizan; Morris J Brown
Journal:  Sci Rep       Date:  2016-04-21       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.